ASH 2023 | Outcomes for patients with multiple myeloma who are TCE and BCMA-exposed are poor
Hira Mian
• 10 Dec 2023
Hira Mian, MD, McMaster University, Hamilton, Canada, discusses a study investigating outcomes for patients with multiple myeloma (MM) who are both triple-class exposed (TCE) and have been treated with BCMA-targeted therapies. The study reveals diverse treatment approaches are used in this patient population, indicating a lack of current standard of care, resulting in poor time-to-next-treatment (TTNT) and time-to-treatment discontinuation (TTD) outcomes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
